TECHNOLOGY - Lobesity Pharmaceuticals and Technologies

“The physiological redundancy offered by insulin and GIP ensured the survival of organisms during times when food was scarce. As food is no longer scarce, this survival advantage appears to have contributed to the current obesity epidemic.”

– Michael O. Boylan, PhD, Lobesity Co-Founder and Chief Scientific Officer

OBESITY EPIDEMIC

KEY TO SURVIVAL

GIP & INSULIN

ANTI-GIP MONOCLONAL ANTIBODY

EFFECT OF ANTI-GIP mAb ON WEIGHT GAIN

KEY EFFECT OF ANTI-GIP mAb ON FAT DEPOSITION

ADDITIONAL BENEFITS OF ANTI-GIP mAb

ANTI-GIP mAb OBESITY TREATMENT SUMMARY

The Lobesity Research Laboratories in Cleveland Ohio

Obesity Co-Founder and Chief Medical Officer M Michael Wolfe, MD is joined by Chief Executive Officer Stephen A. Charles, PhD and Co-Founder and Chief Scientific Officer Michael O. Boylan, PhD at the Lobesity Research Lab. Lobesity is a break-through treatment for obesity that utilizes a proprietary anti-GIP Monoclonal Antibody to target obesity at its roots.